Sana Biotechnology Q4 adjusted EPS misses estimates
Sana Biotechnology, Inc. SANA | 0.00 |
Overview
Biotech firm reported Q4 adjusted EPS miss analyst expectations
Raised $133.7 mln from stock sales, cash runway into late 2026
Outlook
Sana anticipates cash runway into late 2026
Result Drivers
RESEARCH AND DEVELOPMENT EXPENSES: For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million
Company press release: ID:nGNX25tq5m
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q4 Adjusted EPS |
Miss |
-$0.16 |
-$0.13 (7 Analysts) |
Q4 EPS |
|
-$0.21 |
|
Q4 Operating Expenses |
|
$61.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
